Edition:
United Kingdom

Aquestive Therapeutics Inc (AQST.OQ)

AQST.OQ on NASDAQ Stock Exchange Global Market

3.81USD
16 Aug 2019
Change (% chg)

$0.29 (+8.24%)
Prev Close
$3.52
Open
$3.55
Day's High
$3.81
Day's Low
$3.53
Volume
5,862
Avg. Vol
37,924
52-wk High
$19.80
52-wk Low
$2.96

Latest Key Developments (Source: Significant Developments)

Aquestive Therapeutics Q2 Revenue $11.1 Mln Vs $13.9 Mln
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Aquestive Therapeutics Inc ::Q2 REVENUE $11.1 MILLION VERSUS $13.9 MILLION.Q2 LOSS PER SHARE $0.82.REVISING ITS FULL YEAR GUIDANCE AND FINANCIAL OUTLOOK FOR 2019.SEES 2019 TOTAL REVENUES OF $38 MILLION TO $45 MILLION.SEES 2019 NON-GAAP GROSS MARGINS OF 67% TO 69% ON TOTAL REVENUES.SEES 2019 NON-GAAP ADJUSTED EBITDA LOSS OF $50 MILLION TO $52 MILLION.AQUESTIVE THERAPEUTICS SEES 2019 CASH BURN OF ABOUT $60 TO $65 MILLION AFTER CONSIDERING ADJUSTED EBITDA, NET INTEREST EXPENSE AND PRINCIPAL PAID ON DEBT.RAISES FULL YEAR GUIDANCE FOR SUBOXONE-RELATED MANUFACTURING REVENUE.SEES 2019 SUBOXONE AND SANDOZ AUTHORIZED GENERIC MANUFACTURING REVENUE OF $29 MILLION TO $32 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.62, REVENUE VIEW $9.2 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $40.4 MILLION -- REFINITIV IBES DATA.  Full Article

Aquestive Therapeutics Q1 Loss Per Share $0.59
Wednesday, 8 May 2019 

May 8 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q1 REVENUE $12.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $11.6 MILLION.Q1 LOSS PER SHARE $0.59.Q1 EARNINGS PER SHARE ESTIMATE $-0.51 -- REFINITIV IBES DATA.AQUESTIVE IS REAFFIRMING ITS FULL YEAR GUIDANCE AND FINANCIAL OUTLOOK FOR 2019.  Full Article

Aquestive Therapeutics Provides Update Regarding Suboxone Sublingual Film Litigation
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS PROVIDES UPDATE REGARDING SUBOXONE SUBLINGUAL FILM LITIGATION.AQUESTIVE - U.S. COURT DENIED MOTION FOR REHEARING TO REINSTATE PRELIMINARY INJUNCTION AGAINST DR. REDDY'S LABORATORY REGARDING SUBOXONE.AQUESTIVE - DECISION "NOT A JUDGEMENT" IN ONGOING INFRINGEMENT CASES AGAINST DRL AND OTHERS REGARDING POTENTIAL GENERIC PRODUCTS ENTERING U.S. MARKET.  Full Article

Aquestive Therapeutics Sees FY 2018 Revenue $67 Million
Thursday, 20 Dec 2018 

Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS PROVIDES END OF YEAR BUSINESS UPDATE, INCLUDING PROGRESS OF ITS PROPRIETARY CNS ASSETS, FINANCIAL AND LEGAL MATTERS.SEES FY 2018 REVENUE $67 MILLION.SEES END-OF-YEAR CASH AND CASH EQUIVALENTS IN RANGE OF $58 MILLION TO $60 MILLION.EXPECTED NDA FILING FOR EXSERVAN™ (RILUZOLE) ORAL FILM IN JANUARY 2019.PLAN FOR ROLLING SUBMISSION FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM TO BE SUBMITTED IN JANUARY 2019.AQUESTIVE THERAPEUTICS-SEES BRANDED SUBOXONE(BUPRENORPHINE / NALOXONE) FILM IN U.S. & INTERNATIONAL TO BE MAJOR REVENUE CONTRIBUTOR THROUGH AT LEAST 2023.  Full Article

Aquestive Therapeutics Receives Complete Response Letter From FDA
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR TADALAFIL ORAL FILM.AQUESTIVE THERAPEUTICS INC - IN LETTER, FDA REQUESTED LIMITED ADDITIONAL DATA FROM HEALTHY VOLUNTEERS.AQUESTIVE THERAPEUTICS - ANTICIPATE PARTNERING TADALAFIL OF ONCE APPROVED AND CRL HAS NOT CHANGED TIMING OR INTENT.AQUESTIVE THERAPEUTICS - NOTIFIED FDA ABOUT PLANS TO ENGAGE ALTERNATIVE SUPPLIER OF ACTIVE PHARMACEUTICAL INGREDIENT IN TADALAFIL ORAL FILM.  Full Article

Aquestive Therapeutics Q3 Loss Per Share $0.64
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Aquestive Therapeutics Inc ::AQUESTIVE THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q3 LOSS PER SHARE $0.64.Q3 EARNINGS PER SHARE VIEW $-0.48 -- THOMSON REUTERS I/B/E/S.AQUESTIVE THERAPEUTICS - AS OF SEPT 30, 2018, CO'S CASH AND CASH EQUIVALENTS WERE $64.0 MILLION, AS COMPARED TO $17.4 MILLION AS OF DEC 31, 2017.QTRLY REVENUES $13.3 MILLION VERSUS $27.1 MILLION.  Full Article